• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

GENT: Mandatory notification of trade

Gentian Diagnostics
Moss, 29 May 2026

Gentian Diagnostics ASA ("Gentian") has today been notified that the following
transaction has been completed by a primary insider in Gentian:

Matti Heinonen, Chief Executive Officer and primary insider in Gentian, has
purchased 5,000 shares in Gentian at NOK 35.85 per share. Mr. Heinonen owns
15,569 shares and 100,000 options after this transaction.


PDMR notification pursuant to the EU Market Abuse Regulation Article 19 is
attached.

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article
19 and Euronext Oslo Rule Book II.

For further information, please contact: Njaal Kind, Group CFO,
njaal.kind@gentian.no, +47 91 90 65 25
d@gentian.no\, +47 91 90 65 25\